FTC Moves to Settle with CVS Caremark Over Insulin Pricing — $7B in Savings on the Table
By FieldPulse Editorial · March 24, 2026
Tags: Drug Pricing, Policy, Compliance
The FTC has proposed a settlement with CVS Caremark over alleged insulin price manipulation by its PBM unit, with projected savings of $7 billion over a decade. CVS is now the second of the Big 3 PBMs to face a regulatory deal.
Federal regulators moved Monday to settle with CVS Caremark over allegations that its pharmacy benefit management operations manipulated insulin prices to the detriment of patients, proposing a resolution that the FTC projects could generate $7 billion in savings over the next decade.
CVS Caremark is now the second of the three dominant PBMs to face a formal settlement with the commission — following Express Scripts — as federal scrutiny of the pharmacy middlemen intensifies.
The proposed deal still requires approval from the FTC chair before it becomes final.
The FTC's case against the major PBMs has centered on how these firms' rebate structures and formulary decisions inflated list prices for insulin, a drug whose affordability has been a bipartisan flashpoint for years.
By steering patients toward higher-list-price insulins that generated larger rebates — rather than lower-cost alternatives — the agency argued that PBMs contributed to out-of-pocket cost spikes that caused real harm to diabetic patients.
For pharma sales reps, particularly those carrying diabetes portfolios, the PBM settlements are more than a regulatory sidebar.
The way PBMs construct formularies, tier drugs, and negotiate rebates has a direct effect on access, patient co-pays, and ultimately script volume.
If settlements like this one lead to structural changes in how rebates are structured or how formulary decisions are made, the commercial landscape for insulin and adjacent diabetes products could shift meaningfully.
The diabetes market has already been disrupted by the wave of voluntary price cuts that insulin manufacturers made under public pressure in recent years.
A regulatory clampdown on PBM rebate mechanics could further reshape how manufacturers approach pricing strategy and market access negotiations going forward.
The CVS settlement — like the one with Express Scripts before it — also signals that PBM reform is no longer a theoretical legislative debate.
Regulators are using existin.
Source: https://www.statnews.com/pharmalot/2026/03/24/ftc-proposed-deal-cvs-pbm-manipulated-insulin-prices/